RESISTANCE TO VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)

Abstract

Venetoclax, the BCL2 inhibitor, is highly effective for the treatment of chronic lymphocytic leukaemia (CLL), a disease marked by BCL2 overexpression. The highly encouraging results from clinical trials has led to its approval in many jurisdictions, including recent listing in Australia on the Pharmaceutical Benefits Scheme (PBS). In spite of its efficacy, many treated patients will eventually experience disease progression after several years. At the current time, we do not fully understand why resistance emerges. Our research group is well placed to address this question as we have access to one of the largest cohorts of venetoclax-treated patients, and access to serially collected samples..